Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

MiNA Therapeutics Ltd.. (1/7/20). "Press Release: MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases". London.

Organisations Organisation MiNA Therapeutics Ltd.
  Organisation 2 AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
Products Product small activating RNA therapeutic (saRNA)
  Product 2 drug discovery
Index term Index term AstraZeneca–MiNA Therapeutics: saRNA therapeutics, 202001– collab €na research + license option for saRNA therapeutics for metabolic diaseses
Persons Person Habib, Robert (MiNA Therapeutics Ltd 201705 CEO)
  Person 2 May, Stephanie (Trophic Communications 201801 before MacDougall European Office)

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the initiation of a research collaboration with AstraZeneca to evaluate small activating RNA ("saRNA") molecules in metabolic diseases. The collaboration combines MiNA's leading expertise in the discovery and development of saRNA therapeutics with AstraZeneca's experience in identifying and bringing breakthrough treatments to patients with metabolic diseases.

“Many metabolic diseases lack sufficient treatment options to help patients manage their disease and to treat the underlying causes to improve patient outcomes. This is an exciting opportunity for us to collaborate with AstraZeneca, a global leader in the discovery and development of prescription medicines to treat metabolic diseases, that may lead to therapeutic advances for a large number of patients globally,” said Robert Habib, CEO of MiNA. “We continue to evaluate the potential of saRNA therapeutics in a variety of indications, in parallel with advancing our proprietary programs in cancer.”

Under the terms of the agreement MiNA and AstraZeneca will conduct in vitro and in vivo studies that may enable the future development of saRNA therapeutics to treat metabolic diseases through biological pathways not addressable by conventional treatment strategies. Upon completion of these studies, AstraZeneca will have the option to negotiate a license agreement to further develop saRNA molecules that activate an undisclosed gene target identified by AstraZeneca. No further details about the collaboration have been disclosed.

“saRNA molecules are a novel therapeutic modality that upregulate genes and have the potential to access disease-relevant targets that cannot be addressed efficiently with other approaches. We look forward to working with MiNA to investigate the potential of saRNAs further,” said Shalini Andersson, Chief Scientist, New Modalities, Discovery Sciences, R&D, AstraZeneca.

About MiNA Therapeutics

Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases.


MiNA Therapeutics
Robert Habib, CEO
Phone: +44 208 811 6700

Media requests:
Stephanie May or Gretchen Schweitzer
Trophic Communications
Phone: +49 89 2388 7734 or +49 171 185 56 82

Record changed: 2023-06-05


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for MiNA Therapeutics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top